MarketPulse

heart failure

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cytokinetics Q1 2026 Results Due May 5; MYQORZO® Updates Expected

Cytokinetics will report Q1 2026 earnings May 5, discussing MYQORZO® commercialization and pipeline progress in heart failure treatments.
CYTKearnings reportheart failure
GlobeNewswire Inc.GlobeNewswire Inc.··Institute Of Molecular And Clinical Ophthalmology Basel (Iob)

Scientists Develop MitoCatch: Engineered Protein Tech to Deliver Healthy Mitochondria to Damaged Cells

IOB scientists unveil MitoCatch, engineered technology delivering healthy mitochondria to damaged cells. Early data shows improved cell survival in disease models.
NVSheart failureneurodegenerative diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Askbio Inc.

Bayer-Owned AskBio Completes Phase 2 Trial Enrollment for Heart Failure Gene Therapy

AskBio completes enrollment of 173 patients in Phase 2 trial for AB-1002 gene therapy targeting heart failure. Results expected H1 2027.
BAYRYclinical trialheart failure
GlobeNewswire Inc.GlobeNewswire Inc.··Bridgebio Pharma, Inc.

BridgeBio's Acoramidis Cuts Mortality Risk in Half for Rare Heart Disease

BridgeBio reports acoramidis cuts all-cause mortality 44.7% and cardiovascular mortality 49.3% in ATTR-CM patients at Month 54 versus placebo.
BBIOFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

SynCardia's Emperor Heart Set to Challenge Artificial Organ Market at Major Cardiology Conference

SynCardia unveils next-generation Emperor artificial heart at major cardiology conference, advancing fully implantable technology for long-term heart failure treatment.
PMIheart failuretotal artificial heart
GlobeNewswire Inc.GlobeNewswire Inc.··Picard Medical, Inc.

SynCardia's Artificial Heart Technology Takes Center Stage on FOX Business

Picard Medical's SynCardia Systems showcases its Total Artificial Heart technology on FOX Business, highlighting over 2,100 implants worldwide.
PMIFDA approvalheart failure
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Cytokinetics, Incorporated

Cytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials